MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients

Cancer Research

Volumn 73, Issue 6, 2013, Pages 1867-1875

  Pu, Xia ^a   Roth, Jack A ^a   Hildebrandt, Michelle A T ^a   Ye, Yuanqing ^a   Wei, Hua ^a   Minna, John D ^b   Lippman, Scott M ^a,c   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; MICRORNA; MICRORNA 651; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BINDING SITE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DROSHA GENE; FAS GENE; FEMALE; FZD4 GENE; GENE CONTROL; GENE FUNCTION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; RISK REDUCTION; RNA BINDING; RNA GENE; RNA PROCESSING; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR GENE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84875419875     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0873     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 2009;5: 745-55.
3. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008;7:2643-6.
4. Hammond SM. RNAi, microRNAs, and human disease. Cancer Chemother Pharmacol 2006;58 Suppl 1:s63-8.
5. Croce CM. Oncogenes and cancer. N Engl J Med 2008;358:502-11.
6. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
7. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res 2005;65:3509-12.
8. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
9. Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 2008;68:2530-7.
10. Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA, et al. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila Pa) 2008;1: 460-9.
11. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, et al. Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res 2010;70: 9765-76.
12. Horikawa Y, Wood CG, Yang H, Zhao H, Ye Y, Gu J, et al. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res 2008; 14:7956-62.
13. Campayo M, Navarro A, Vinolas N, Tejero R, Munoz C, Diaz T, et al. A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma. PLoS One 2011;6:e22509.
14. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 30 untranslated region increases non-small cell lung cancer risk. Cancer Res 2008;68: 8535-40.
15. Teo MT, Landi D, Taylor CF, Elliott F, Vaslin L, Cox DG, et al. The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis 2012;33: 581-6.
16. Zhang L, Liu Y, Song F, Zheng H, Hu L, Lu H, et al. Functional SNP in the microRNA-367 binding site in the 30UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci U S A 2011;108: 13653-8.
17. Spitz MR,HongWK, AmosCI,WuX, Schabath MB, Dong Q, et al.Arisk model for prediction of lung cancer. J Natl Cancer Inst 2007;99: 715-26.
18. Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, Yang H, et al. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila Pa) 2009;2:617-24.
19. Bao L, Zhou M,WuL, Lu L, Goldowitz D, Williams RW, et al. PolymiRTS Database: linking polymorphisms in microRNA target sites with complex traits. Nucleic Acids Res 2007;35:D51-4.
20. Zhang H, Singer BH. Recursive partitioning and applications. 2nd ed. New York: Springer; 2010.
21. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5.
22. Uramoto H, Osaki T, Inoue M, Taga S, Takenoyama M, Hanagiri T, et al. Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 1999;35:1462-5.
23. Park JY, Lee WK, Jung DK, Choi JE, Park TI, Lee EB, et al. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer. Clin Cancer Res 2009;15:1794-800.
24. Huang CR, Jin ZX, Dong L, Tong XP, Yue S,Kawanami T, et al. Cisplatin augments FAS-mediated apoptosis through lipid rafts. Anticancer Res 2010;30:2065-71.
25. Katoh M. WNT signaling in stem cell biology and regenerative medicine. Curr Drug Targets 2008;9:565-70.
26. Hu L, Wu C, Zhao X, Heist R, Su L, Zhao Y, et al. Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2012;18:5507-14.
27. Huang YT, Heist RS, Chirieac LR, Lin X, Skaug V, Zienolddiny S, et al. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol 2009;27:2660-7.
28. NiuNMDPD, Schaid DJPD, Abo RPPD, Kalari KPD, Fridley BLPD, Feng QPD, et al. Genetic association with overall survival of taxane-treated lung cancer patients - A genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.BMC Cancer 2012;12:422.
29. Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, et al. Genome-wide association study on overall survival of advanced nonsmall cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 2011;6:132-8.
30. Tan XL, Moyer AM, Fridley BL, Schaid D, Niu N, Batzler A, et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2011;17:5801-11.
31. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 2011;103:817-25.
32. Reed MF, Molloy M, Dalton EL, Howington JA. Survival after resection for lung cancer is the outcome that matters. Am J Surgery 2004;188: 598-602.
33. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010;28:29-34.